Newly Granted US Composition of Matter Patent Extends

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Newly Granted US Composition of Matter Patent Extends Exclusive Protection for VBL Therapeutics' Lead Drug Candidate VB-111 Until October 2033

TEL AVIV, Israel, Dec. 1, 2015 (GLOBE NEWSWIRE) -- VBL Therapeutics (NASDAQ: VBLT ), today announced the grant of US Patent No. 9,200,056, entitled "A Fas-Chimera Adenovirus Vector" by the United State Patent Office (USPTO) which covers VB-111, VBL's lead drug candidate. This composition patent provides intellectual property protection for VB-111 in the US until October 2033 before any patent term extension.

"This granted patent is exceptionally important to VBL since it secures IP rights for VB-111 in multiple oncology indications until at least 2033. It is a strong addition to our Vascular Targeting System (VTS™) portfolio," said Erez Feige, Ph.D., Vice President of Business Operations of VBL Therapeutics.

"The issuance of this patent gives us at least 18 years of exclusivity on our lead drug candidate, VB-111, which is currently being investigated in our GLOBE Phase 3 pivotal trial for recurrent GBM, in addition to Phase 2 trials in platinum-resistant ovarian cancer and radioactive-iodine refractory differentiated thyroid cancer. With positive data from three cancer indications and such a long IP lifespan, our goal is to exploit the full potential of VB-111 in multiple oncology indications," said Dror Harats, M.D., CEO of VBL Therapeutics.

Recently, VBL presented data from its Phase 2 trial of VB-111 in recurrent glioblastoma multiforme (rGBM), which demonstrated that the overall survival rate for patients treated with VB-111 in combination with bevacizumab (Avastin®) upon disease progression (continuous exposure cohort) was 57% at 12 months. This compares with an overall 12 month survival of 28% (range 16% to 38%) in the data pooled from four Avastin® studies (p = 0.007).

VBL's pivotal Phase 3 GLOBE study in rGBM is comparing VB-111 in combination with bevacizumab to bevacizumab alone and is recruiting about 252 patients in the US, Canada and Israel. The study is proceeding under a Special Protocol Assessment (SPA) granted by the FDA, with full endorsement by the Canadian Brain Tumor Consortium (CBTC). VB-111 has received orphan drug designation in the United States and Europe and was granted Fast Track designation by the FDA for prolongation of survival in patients with glioblastoma that has recurred following treatment with standard chemotherapy and radiation.

About VB-111

VB-111 is a novel, intravenously-administered, targeted anti-angiogenic agent that utilizes VBL's proprietary Vascular Targeting System (VTS™) to target endothelial cells in the tumor vasculature for cancer therapy. VB-111 contains a non-replicating adenovirus, a proprietary modified murine pre-proendothelin promoter (PPE-1-3x) and a Fas-Chimera transgene which is specifically activated in angiogenic tumor blood vessels, leading to their apoptosis.VB-111 is the first agent based on transcriptional targeting of tumor endothelium to be assessed in a clinical trial.

VB-111 completed a Phase 2 study in recurrent glioblastoma (rGBM), which showed a statistically significant improvement in overall survival in patients treated with VB-111 followed by VB-111 in combination with bevacizumab upon disease progression, compared to patients treated with VB-111 followed by bevacizumab alone. VB-111 is also being studied in a Phase 2 trial in recurrent platinum-resistant ovarian cancer, which provided promising evidence of clinical benefit in an interim analysis, and in a Phase 2 study in recurrent, iodine-resistant differentiated thyroid cancer, which provided evidence of disease stabilization and a positive safety profile. VB-111 has Fast Track Designation for recurrent glioblastoma in the U.S. and orphan drug status for glioblastoma in both the U.S. and EU.

About VBL

Vascular Biogenics Ltd., operating as VBL Therapeutics, is a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of first-in-class treatments for cancer. The company's lead oncology product candidate, VB-111, is a gene-based biologic that is initially being developed for recurrent glioblastoma (rGBM), an aggressive form of brain cancer. VB-111 has received orphan drug designation in both the United States and Europe and was granted Fast Track designation by the FDA for prolongation of survival in patients with glioblastoma that has recurred following treatment with standard chemotherapy and radiation. VBL Therapeutics' pivotal Phase 3 GLOBE trial of VB-111 in rGBM is ongoing under a special protocol assessment granted by the FDA.

Forward-Looking Statements

This press release contains forward-looking statements. Forward-looking statements include all statements that do not relate solely to historical or current facts, and can be identified by the use of words such as "may," "will," "expect," "project," "estimate," "anticipate," "plan," "believe," "potential," "should," "continue" or the negative versions of those words or other comparable words. These forward-looking statements are not promises or guarantees and involve substantial risks and uncertainties. Among the factors that could cause actual results to differ materially from those described or projected herein include uncertainties associated generally with research and development, clinical trials and related regulatory reviews and approvals, and the risk that historical clinical trial results may not be predictive of future trial results. In particular, enforcement of our patent rights could require resources and involve us in litigation, the result of which is inherently uncertain. In addition, it is possible that our patent covering VB-111 may be disputed by third parties. A further list and description of these risks, uncertainties and other risks can be found in the company's regulatory filings with the U.S. Securities and Exchange Commission. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. VBL Therapeutics undertakes no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise.

Avastin ® is a registered trademark of Genentech Inc.

INVESTOR CONTACT: Michael Rice, Founding Partner LifeSci Advisors, LLC 646-597-6979

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Pony.ai & Toyota Launch 1,000 Gen-7 Robotaxis in China

Updated Category News Views 74

Revving Up the Autonomous Ride Revolution Not every day you see two giants, Pony.ai and Toyota, join forces to shake up the way folks get from A to B. But here we are — they’ve fired up their engines in Guangzhou, unleashing their Gen-7 bZ4X Robotaxis for commercial use. And let me tell you, this is no shot in the dark. With plans to dot about 1,000 of these...

Continue Reading
SOBER CAFFEINE™: Modern Energizer Without the Bull

Updated Category News Views 37

Shed the Cans and Embrace Convenience I'm sure you've had a run-in with the standard energy drink routine. You know, the massive cans, a gut punch of sugar, and the inevitable crash that follows? Sobriety Supplements LLC decided enough is enough and rolled out something that just makes sense—SOBER CAFFEINE™ capsules. This little pill is a godsend for folks sick of...

Continue Reading
Ampace Focuses on Battery Safety Standards at RE+ 2026

Updated Category News Views 113

Battery Safety Takes Center Stage No mystery here: the safety of our beloved lithium-ion batteries is crucial, especially as AI data centers sprout like weeds. At RE+ 2026, Ampace is putting its chips on the table by spotlighting this hot topic. Dr. Drew Feng, their Chief Safety Officer, is set to reveal the big guns: findings from the PU100 large-scale fire test. Mark...

Continue Reading
Employment Law Suit Hits ABC: Alleged Wage Violations

Updated Category News Views 275

ABC Under Fire for Labor Code Violations You know it's a rocky road when a company like American Broadcasting Companies, Inc. lands itself in hot water with accusations riding high on labor law violations. People yapping about lunch breaks? Well, that’s the ball game here. Meal and Rest Break Controversies According to a recent lawsuit filed by Blumenthal Nordrehaug...

Continue Reading
FFR's Michigan Milestone and Major Robotics Update

Updated Category News Views 160

Nobody's going to argue that breaking into new territories isn't a gamble, but sometimes you just need to roll the dice. FF EAI Robotics Ecosystem Inc. (NASDAQ: FFR) is banking on their move with Aegis Ultra robots, making an academic splash at Central Michigan University. This isn't just about ticking off another state; it's about stacking the deck with new...

Continue Reading
Viking Ventures: Impacts of VK2735 on Obesity Examined

Updated Category News Views 292

Viking Therapeutics Reveal Surprising Data on VK2735 The latest from Viking Therapeutics' camp is giving obesity some serious food for thought, with new data making waves at the ObesityWeek® 2026 meeting. Their investigational dual agonist, VK2735, seems to be shaking things up, as early phase clinical data shows an impressive 74% of participants managed to improve at...

Continue Reading
Pan-Mass Challenge Gifts $80M to Dana-Farber for 2026

Updated Category News Views 308

A Momentous Gift in a Crunch Time for Cancer Research Biking and philanthropy might seem like an odd duo, but let me tell you, the Pan-Mass Challenge (PMC) is making that partnership look like peanut butter and jelly. This year, PMC rolled out a jaw-dropping $80 million gift to the Dana-Farber Cancer Institute. You heard right—eighty million smackeroos. Talk about going...

Continue Reading
Ambrosia Biosciences Unveils Promising Nonclinical Metabolic Data

Updated Category News Views 431

Ambrosia's Latest Nonclinical Revelations Ambrosia Biosciences has just thrown out some major bait at ObesityWeek® 2026. The highlight? New nonclinical data profiles for two of their understudy small molecule programs—AMB-895 and AMB-131. It may sound niche, but in this sector, promising data spins heads. Their GLP-1 receptor agonist, AMB-895, and GIP receptor...

Continue Reading
IDEAYA's IDE101: A New Front in Cancer Battle

Updated Category News Views 407

IDEAYA's Bold Move in Precision Medicine IDEAYA Biosciences, no stranger to the frontlines of cancer treatment, is gunning for a breakthrough with their latest pick, IDE101. They're jumping into the ring with a potential first-in-class inhibitor targeting CDKN2A-deficiency—a notorious player in the solid tumor game. They're not just mixing things up for the sake of it;...

Continue Reading
Novo's CagriSema Trials Show Promising Weight Loss

Updated Category News Views 421

Decoding CagriSema's Promise Let me tell you, when those corporate folks from Novo Nordisk announce something big like their investigational drug CagriSema at ObesityWeek® 2026, it’s time to take notice. This isn’t just your average press release about some new weight loss fad. We’re talking about a phase 3 REDEFINE 1 trial that opens up a treasure chest of data...

Continue Reading

Top 5 Most Recently Viewed Articles

Daniel Pink on Leadership and Workplace Evolution Insights

Updated Category News Views 424

Exploring Leadership in a Changing Workplace The recent episode of Info-Tech Research Group's podcast, Digital Disruption, highlights a thought-provoking discussion with bestselling author Daniel Pink, focusing on how leaders can adapt in a time he describes as 'the great sort'. This term encapsulates the ongoing transformation in our approach to work, leadership, and the...

Continue Reading
MORSE Corp's Community Cleanup Initiative: Making an Impact

Updated Category News Views 240

MORSE Corp's Commitment to Community Service MORSE Corp recently dedicated an entire day to community service by hosting a cleanup initiative at local beaches and parks. On a beautiful Wednesday, the organization mobilized its team to gather at a coastal spot to improve the environment and promote community spirit. This initiative is part of their annual effort to...

Continue Reading
FDA's New Proposal to Enhance Nutrition Awareness on Food Labels

Updated Category News Views 125

Revolutionizing Nutrition Transparency for Consumers Today, the U.S. Food and Drug Administration (FDA) is taking significant steps towards improving consumer awareness about the nutritional value of packaged foods. A new proposal dictates that most packaged foods will require a prominent front-of-package (FOP) nutrition label. This initiative is part of a broader...

Continue Reading
CW Bancorp Declares Quarterly Dividend for Shareholders

Updated Category News Views 150

CW Bancorp Announces Dividend Declaration CW BANCORP (OTCQX: CWBK), the parent company of CommerceWest Bank, has approved a quarterly cash dividend. The news comes as the company continues to prioritize shareholder value while supporting its growth journey. Details of the Cash Dividend The Board of Directors of CW Bancorp declared a cash dividend of $0.23 per common...

Continue Reading
Universal Electronics Unveils QuickSet homeSense at CES Event

Updated Category News Views 348

Universal Electronics Introduces QuickSet homeSense Technology Universal Electronics Inc. (NASDAQ: UEIC) has made headlines by launching its innovative QuickSet homeSense technology. This introduction took place at the prestigious International Consumer Electronics Show (CES) where the spotlight is often on groundbreaking tech. UEI, a leader in wireless control solutions,...

Continue Reading